Get the Stockscreener App
71.01
2.72%
1.88
After Hours:
71.35
0.34
+0.48%
Spyre Therapeutics Inc stock is traded at $71.01, with a volume of 2.01M.
It is up +2.72% in the last 24 hours and up +49.24% over the past month.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
See More
Previous Close:
$69.13
Open:
$70.645
24h Volume:
2.01M
Relative Volume:
1.97
Market Cap:
$6.13B
Revenue:
$688.00K
Net Income/Loss:
$-135.82M
P/E Ratio:
-34.17
EPS:
-2.078
Net Cash Flow:
$-169.41M
1W Performance:
+3.47%
1M Performance:
+49.24%
6M Performance:
+210.77%
1Y Performance:
+403.97%
1-Day Range:
$70.21
$73.22
1-Week Range:
$67.18
$76.00
52-Week Range:
$12.29
$76.00
Spyre Therapeutics Inc Stock (SYRE) Company Profile
Name
Spyre Therapeutics Inc
Sector
Industry
Phone
(617) 651-5940
Address
221 CRESCENT STREET, WALTHAM
Compare SYRE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SYRE
Spyre Therapeutics Inc
|
71.01 | 5.96B | 688.00K | -135.82M | -169.41M | -2.078 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Spyre Therapeutics Inc Stock (SYRE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-26 | Initiated | Raymond James | Strong Buy |
| Dec-18-25 | Initiated | Mizuho | Outperform |
| Dec-17-25 | Initiated | Citigroup | Buy |
| Sep-26-25 | Initiated | Deutsche Bank | Buy |
| Apr-08-25 | Initiated | Leerink Partners | Outperform |
| Mar-18-25 | Initiated | Wolfe Research | Outperform |
| Sep-04-24 | Initiated | Wedbush | Outperform |
| Jul-16-24 | Initiated | Evercore ISI | Outperform |
| May-02-24 | Initiated | Robert W. Baird | Outperform |
| Mar-01-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-20-23 | Initiated | BTIG Research | Buy |
| Dec-11-23 | Initiated | Guggenheim | Buy |
| Dec-11-23 | Initiated | Jefferies | Buy |
| May-04-20 | Initiated | Piper Sandler | Overweight |
| Mar-21-19 | Initiated | JP Morgan | Overweight |
| Sep-04-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Apr-24-18 | Initiated | Evercore ISI | Outperform |
| Mar-14-18 | Reiterated | Needham | Buy |
View All
Spyre Therapeutics Inc Stock (SYRE) Latest News
Stifel raises Spyre stock price target to $107 on UC data strength - Investing.com
Spyre Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Spyre Therapeutics Q1 Loss Widens - Moomoo
Earnings Flash (SYRE) Spyre Therapeutics Posts Q1 Net Loss $0.74 a Share, vs. FactSet Est of $0.67 Loss - marketscreener.com
Spyre Therapeutics, Inc. Q1 operating expenses USD 45.641 million - marketscreener.com
According to the latest financial data from biopharmaceutical company Spyre Therapeutics Inc, as of March 31, 2026, the company's total cash, cash equivalents, and marketable securities amounted to 741.5 millions USD. - Bitget
Biotech Spyre lines up six 2026 trial readouts with $1.2B cash - Stock Titan
Spyre Therapeutics, Inc. 1Q 2026: Net loss $(69.0)M, EPS $(0.74) — 10-Q Summary - TradingView
Earnings Flash (SYRE) Spyre Therapeutics Posts Q1 Net Loss $0.74 a Share, Vs. FactSet Est of $0.67 Loss - Moomoo
Spyre Therapeutics posts wider-than-expected Q1 net loss - TradingView
Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
Spyre Therapeutics: Q1 Earnings Snapshot - 10TV
SYRE: Strong clinical progress and robust cash position support long-term growth despite higher net loss - TradingView
Spyre Therapeutics (SYRE) widens Q1 loss but builds $1.18B pro forma cash runway - Stock Titan
Spyre Therapeutics (NASDAQ: SYRE) widens Q1 2026 loss but ends quarter with $741.5M in cash and securities - Stock Titan
MSN Money - MSN
Spyre Therapeutics (SYRE) price target increased by 42.03% to 88.06 - MSN
Spyre Therapeutics stock hits 52-week high at $75.30 By Investing.com - Investing.com Nigeria
Insider Sell: Cameron Turtle Sells 15,000 Shares of Spyre Therap - GuruFocus
Insider Sell: Cameron Turtle Sells 15,000 Shares of Spyre Therapeutics Inc (SYRE) - GuruFocus
Insider Selling: Spyre Therapeutics (NASDAQ:SYRE) CFO Sells 12,500 Shares of Stock - MarketBeat
Insider Selling: Spyre Therapeutics (NASDAQ:SYRE) CEO Sells 15,000 Shares of Stock - MarketBeat
Spyre Therapeutics (NASDAQ:SYRE) Insider Sells $5,600,809.50 in Stock - MarketBeat
Spyre Therapeutics CEO Cameron Turtle sells $1.07m in shares By Investing.com - Investing.com India
Spyre Therapeutics CMO Sheldon Sloan sells $5.6m in shares By Investing.com - Investing.com India
Spyre Therapeutics CEO Cameron Turtle sells $1.07m in shares - Investing.com
Spyre Therapeutics CMO Sheldon Sloan sells $5.6m in shares - Investing.com
Spyre Therapeutics CFO Scott Burrows sells $892,125 in stock By Investing.com - Investing.com Canada
Spyre Therapeutics CFO Scott Burrows sells $892,125 in stock - Investing.com
Spyre (SYRE) CFO sells 12,500 shares under Rule 10b5-1 plan - Stock Titan
Spyre Therapeutics (NASDAQ:SYRE) Trading Down 6.3%Here's What Happened - MarketBeat
Option exercise, 10b5-1 sale reported by SYRE (NASDAQ: SYRE) - Stock Titan
SYRE (NASDAQ: SYRE) Form 144: 27,500 shares tied to option exercise - Stock Titan
Spyre Therapeutics Announces Grants of Inducement Awards - The Manila Times
Four new Spyre hires get stock options priced at $69.42 a share - Stock Titan
Spyre Therapeutics (SYRE) Is Up 7.5% After Positive SKYLINE Data And $463.5 Million Raise - Yahoo Finance
SYRE stock jumps more than 70% in a month: What is driving this rally? - MSN
Spyre Therapeutics stock hits 52-week high at $75.30 - Investing.com
Pictet Asset Management Holding SA Cuts Stake in Spyre Therapeutics, Inc. $SYRE - MarketBeat
SYRE stock marks best session in about 3 years — here’s why - MSN
Spyre Therapeutics (NASDAQ:SYRE) Reaches New 1-Year HighHere's What Happened - MarketBeat
Spyre Therapeutics Secures $463.5 Million Through Public Stock Offering - HarianBasis.co
Is Spyre Therapeutics (SYRE) One of the Small-Cap Stocks That Are On Fire Right Now? - Insider Monkey
JonesTrading Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Maintains Target Price $95 - Moomoo
10 Small-Cap Stocks That Are On Fire Right Now - Insider Monkey
LifeSci Capital Maintains Spyre Therapeutics(SYRE.US) With Buy Rating, Cuts Target Price to $105 - Moomoo
Universal Beteiligungs und Servicegesellschaft mbH Raises Stake in Spyre Therapeutics, Inc. $SYRE - MarketBeat
Spyre Therapeutics Drug SPY001 Achieves Success in Ulcerative Colitis Trial - HarianBasis.co
Spyre Therapeutics prices upsized $403M stock deal; gross proceeds exceed initial $300M goal - MSN
Spyre Therapeutics (SYRE): Favorite Stock of Elite Money Managers - Insider Monkey
Apellis Pharmaceuticals is the most overbought healthcare stock as Q1 earnings roll on - MSN
Spyre Therapeutics Inc Stock (SYRE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):